Board of Directors

Luc-André Granier M.D., Ph.D.

Chairman and CEO

Luc-André co-founded Advicenne in 2007 and is the Company’s CEO, Medical Director and Chairman of the Board. Luc-André is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system with more than 25 years’ experience in the pharmaceutical (Eli Lilly and Co) and biotechnology (Synt:em, Forenap) industries. He has overseen a large number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, mainly in the fields of pain, migraine, neuro-degenerative diseases and psychiatric disorders. He was responsible for the successful proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004.

Luc-André obtained his degree as a Doctor of Medicine and Doctor of Science (in Biochemistry and Molecular and Cellular Biology) at the Louis Pasteur University in Strasbourg, France. He is a member of several national and international scientific societies, mainly in the field of pain, epilepsy (ILAE*) and renal diseases (ASN**, IPNA ***).

* International League Against Epilepsy, **American Society of Nephrology, *** International Pediatric Nephrology Society

Philippe Boucheron

Philippe has more than 20 years’ of life science investment experience. He is Deputy Chief – Life Sciences Investment at Bpifrance.

Between 1993 and 1996, Philippe Boucheron worked as an associate at BioCapital LP, one of the largest Canadian venture capital funds focusing on healthcare.
From 1997 to 2000, he directed the mid-caps equity research team at ING Barings Ferri, Paris, where he spent a significant part of his time following French and European listed biotech companies. In 2000, he co-founded the Bioam Funds dedicated to early-stage life science investments and became Investment Manager, then in 2004 Managing Partner.

After the merger of Bioam with CDC Entreprises in July 2010, Philippe Boucheron joined the CDC Entreprises life sciences’ team as Investment Manager.
In 2013, CDC Entreprises, FSI and Oséo merged to create Bpifrance. Since then, he is deputy chief of the Life Sciences Investment Business Unit and sits on Bpifrance Investissement’s Committee. Philippe Boucheron also sits on the boards of Ademtech, Integragen, SSI, ART, Supersonic Imagine and CorWave. Philippe Boucheron holds an engineering degree in Biochemical Engineering and Microbial genetics from the Institut National des Sciences Appliquées in Toulouse, a MSc in Biochemical Engineering from the Ecole Polytechnique.

Françoise Brunner-Ferber Ph.D.

Françoise has more than 25 years’ Clinical Pharmacology experience, working for Merck Sharp and Dohme, Johnson and Johnson, and later for Marion Merrell Dow through its mergers with Hoechst Marion Roussel and Aventis. She spent 7 years as Head of the Zurich Subregion (MSD) and subsequently 10 years as Senior Director and Head of Clinical Pharmacology Europe. Her responsibilities included strong interfaces with preclinical development and research groups, aiming at a coordinated drug development strategy across the Atlantic. She has a keen interest in animal models, first-in-man studies, surrogate markers, and PK/PD relationship to support mechanisms of action and dose selection. She founded Brunner Naga, a consultant company, in 2001.

Renaud du Lac

He is the President and Chairman of the Board of Directors of SOCRI, SCR as well as Chief Executive Officer, President, and Director of iXO Private Equity. He was previously a Deputy Managing Director of IRDI Midi-Pyrénées which he joined in 1989 and left in 2012, and groupe IRDI/iXO PE in 2003. Renaud has held various positions at Exxon working in production, marketing, and strategic development. He is a Director of IRDI Midi-Pyrénéesand AFIC, and was a Director at Association Française des Investisseurs en Capital.

He holds a Masters from Paris Dauphine University and graduated from Ponts et Chaussées (Engineer School).

Charlotte Sibley

Ms. Charlotte Sibley’s career in the healthcare industry spans 40 years. Her career includes contributing her expertise in market research at Pfizer, and in the medical device sector at Johnson & Johnson. Ms. Sibley also expanded her expertise to global pharma at Bristol-Myers Squibb and Pharmacia (now Pfizer), in biotech at Millennium Pharmaceuticals (now Takeda Oncology), and in consumer products at Lipton. She established the U.S. operations for a leading UK-based market research company, achieving profitability in 18 months in a highly competitive environment. Ms. Sibley also worked in New York at Donaldson, Lufkin & Jenrette as a security analyst for the pharmaceutical industry. She holds an MBA in Finance and Marketing from the University of Chicago Booth Graduate School of Business.

Ms. Sibley was named by the Healthcare Businesswomen’s Association 2008 Woman of the Year, in recognition of her leadership, business expertise and mentoring, and was among those named PharmaVoice’s Most Inspiring People in Pharma in 2006. Ms. Sibley serves on the Board of Directors of privately held Taconic Biosciences, Inc. and Fort Hill Company. Through 2014 she was a member of the Board of American Pacific Corporation (NASDAQ: AMPAC), a leading custom manufacturer of pharmaceutical ingredients and propulsion products. She is a National Association of Corporate Directors (NACD) Board Leadership Fellow and Governance Fellow.

Thibaut Roulon Ph.D.

Thibault is currently Investment Director – Life Science Investments Bpifrance. A scientist by training Thibaut Roulon has been an investor in life sciences companies since 2005. In 2005 he joined Bioam Gestion, a venture capital firm investing in life sciences companies. In 2010, Bioam merged with CDC Enterprises, a leading French private equity firm. Thibaut is responsible for managing investments in life sciences companies through Bioam and InnoBio funds.

Thibaut started his career as a scientist at Anosys Inc. (Menlo Park, CA, USA), a company developing cancer immunotherapeutics. Thibaut is a graduate of the Ecole Centrale de Paris and holds a Ph.D. from the Pierre & Marie Curie University.

Jean-Michel Petit

Jean-Michel heads the venture capital practice of IRDI Gestion where he manages the seed fund IRDInov investing in start-ups located in the South-West of France. He serves on the boards of several portfolio companies such as Gamamabs, Fineheart, EnobraQ, Telecom Design, Ademtech and LDL Technology. Before joining IRDI Gestion, he spent four years at CDP Capital as part of the Life Sciences venture capital team based initially in Montreal and then in Paris where he made a range of international investments (mostly in the US). Prior to CDP Capital, he worked for a regional fund based in Montreal, Canada.

Jean-Michel graduated from Chimie ParisTech and holds an MSc degree from Montreal University and an MBA from McGill.

Catherine Dunand

Catherine Dunand has held several executive posts in the pharmaceutical industry, among them, International Marketing Manager, Head of International Marketing, and Head of International Profit Centers. Working with companies such as Roussel Uclaf and Hoechst Marion Roussel (now parts of SANOFI), Dunand has also conducted several M&A assignments and reorganization projects.

Following her work in the pharmaceutical industry, Dunand served as the CEO of several SMEs, leading two successive LBOs.

For the last eight years, she has dedicated herself to consulting and non-executive assignments for growing SMEs, including family owned companies, listed companies and private equity funds. In addition, she holds minority stakes in several private equity investments.

Following the sale of pharmaceutical company HRA, Dunand helped to found CEMAG INVEST, a family office investing in healthcare and B to B services. She currently serves as the company’s CEO. Catherine is graduated from Ecole Centrale de Lyon, Insead (MBA), Sciences Po/IFA – Institut Français des Administrateurs (Non-Executive Director certification).

André Ulman PhD, MD

Non-voting member (Censor)

André Ulmann’s career spans some 30 years in research and the pharmaceutical industry as well as medical practice. André actively advises Advicenne from conception through to drug development.

André Ulmann is currently a Director of HRA Pharma which he founded and managed until 2009 before assuming the presidency. HRA Pharma launched Norlevo, better known as the “morning after pill”, in 1999. Norlevo is now available in more than 50 countries and has made HRA Pharma a pioneer in emergency contraception. Under Andre’s leadership, HRA Pharma has become a socially conscious pharmaceutical company that designs and develops medical products and devices for the treatment of rare diseases and unmet medical needs.

André Ulmann is a Doctor of Medicine and Doctor of Science, and, began his career practicing Nephrology at Hopital Neckerin Paris (France).